There is limited research aimed at understanding the effects of multiple sclerosis (MS) in the Latino community. Although a study conducted in South California found the prevalence lower in Latino individuals than in Black or White individuals, clinicians are seeing a rise in MS diagnoses in the Hispanic community.
Daniel Ontaneda, M.D., Ph.D., of the Cleveland Clinic, and his colleagues used a patient registry to research multiple sclerosis in the Latino community.
To better understand how MS affects Latino individuals living with this disease, Daniel Ontaneda, M.D., Ph.D., and his colleagues conducted a retrospective, cross-sectional study utilizing data from individuals in the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) registry. MS PATHS gathers patient data generated from regular office visits to assist in research programs.
Ontaneda, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discussed the findings in a poster presentation this April at the 2023 American Academy of Neurology (AAN) Annual Meeting in Boston, Massachusetts. The abstract was also published late last month in the journal Neurology.
The study included 388 Latinxoand 5,726 non-LatinoWhite patients with MS diagnoses. Each participant had undergone a brain MRI within one year of clinical visits. In comparison with White participants, Latino patients were younger (45 years vs.53 years) and had shorter disease duration (17 years vs. 20 years).
Despite these differences, Latino patients showed lower processing speed, slower walking speed, higher T2 lesion volume (an MRI marker of MS disease progression), and lower thalamic, cortical, and deep gray matter volume.
Ontaneda and colleagues concluded that Latinx patients with MS have more physical disability, cognitive dysfunction, loss of deep gray matter, and greater tissue injury than non-Latino White individuals despite being younger and having a shorter disease duration.
Blood-Based Immune Signatures Identified to Personalize MS Treatment
July 11th 2024A new study out of Germany, published in Science Translational Medicine in June, looked at peripheral blood mononuclear cells and serum collected from two independent cohorts of patients with MS to identify three endophenotypes of the disease.
Read More
TG Therapeutics, Briumvi’s manufacturer, currently recommends that patients who can get pregnant use an effective method of contraception during treatment with Briumvi and for at least six months after the last Briumvi dose. A pregnancy test before each treatment is also recommended.
Read More